CTI BIOPHARMA CORP. (NASDAQ:CTIC) Files An 8-K Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition.
CTI BioPharma Corp. (the Company) will be providing a corporate
update, including preliminary, unaudited estimates of its cash
and cash equivalents balance and capital structure as of December
31, 2016, to analysts and investors through a series of
one-on-one meetings.
slides to be used in these presentations attached as Exhibit 99.1
hereto, are being furnished and not filed to Item 2.02 of Form
8-K. Such information shall not be deemed to be filed for
purposes of Section 18 of the Securities Exchange Act of 1934, as
amended (the Exchange Act), or otherwise subject to the
liabilities of that section, and shall not be deemed to be
incorporated by reference into any of the Companys filings under
the Securities Act of 1933, as amended (the “Securities Act”), or
the Exchange Act whether made before or after the date hereof and
regardless of any general incorporation language in such filings,
except to the extent expressly set forth by specific reference in
such a filing.
reference into this Item 7.01.
Exhibit 99.1 hereto and are being furnished and not filed to Item
7.01 of Form 8-K. Such information shall not be deemed to be
filed for purposes of Section 18 of the Exchange Act, or
otherwise subject to the liabilities of that section, and shall
not be deemed to be incorporated by reference into any of the
Companys filings under the Securities Act or the Exchange Act
whether made before or after the date hereof and regardless of
any general incorporation language in such filings, except to the
extent expressly set forth by specific reference in such a
filing.
|
Exhibit
No.
|
Description
|
Location
|
||
|
99.1
|
CTI BioPharma Corp. Presentation Slides.
|
Furnished herewith.
|
About CTI BIOPHARMA CORP. (NASDAQ:CTIC)
CTI BioPharma Corp. (CTI) is a biopharmaceutical company focused on the acquisition, development and commercialization of targeted therapies covering a spectrum of blood-related cancers to patients and healthcare providers. The Company is primarily focused on commercializing PIXUVRI in select countries in the European Union, for multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (NHL). It is also engaged in evaluating pacritinib for the treatment of adult patients with myelofibrosis. Its earlier stage product candidate, tosedostat, is an oral, once-daily aminopeptidase inhibitor that has demonstrated responses in patients with acute myeloid leukemia (AML). It also evaluates its pipeline candidate paclitaxel poliglumex (Opaxio), which targets solid tumors. It is evaluating Opaxio through cooperative group sponsored trials and investigator-sponsored trials (ISTs), such as the ongoing maintenance therapy trial in patients with ovarian cancer. CTI BIOPHARMA CORP. (NASDAQ:CTIC) Recent Trading Information
CTI BIOPHARMA CORP. (NASDAQ:CTIC) closed its last trading session up +0.34 at 4.80 with 772,988 shares trading hands.
